The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Abdominal & Pelvic | Hyperthermia in Treating Patients with Painful Unresectable Abdominal or Pelvic Malignancy | ADIPOLAB-001 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Bladder Cancer | A Phase 3, Randomized, Open-Label Study to Evaluavate Perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus Neodjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) | KEYNOTE B15 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Bladder Cancer | A Randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in cisplatin-ineligible participants with muscle-invasive bladder cancer | KEYNOTE 905 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Muscle-invasive bladder cancer | A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) | KEYNOTE 992 | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Sunway Medical Centre | Dr Nik Muhd Aslan | +603 – 74919191/ 603-8601 1079 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Breast Cancer | Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients with APOBEC3B | AUROR | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE |
| Triple Negative Breast Cancer | A Phase III Double-blind Randomised Study Assesing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) | CAPITELLO-290 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE | |||
| Metastatic Triple-Negative Breast Cancer | Kuala Lumpur Hospital (HKL) | Dr Eznal Izwadi Mohd Mahidin | 603 – 2615 5555, ext 5833 | N/A | ||
| Breast Cancer | Studies of Epigenetic changes in blood samples in breast cancer patients | EPIGENECTIC | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
N/A |
| Kuala Lumpur Hospital (HKL) | Dr Ros Suzanna Ahmad Bustamam | 603 – 2615 5555, ext 5833 | N/A | |||
| HER2+ Breast Cancer | A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation | EPIK-B2 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) |
CLICK HERE | |||
| Metastatic or Advanced Triple Negative Breast Cancer | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | EPIK-B3 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 010 – 4346150 (Suganiya) |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | +603 – 7806 0845 | CLICK HERE | |||
| Breast Cancer | Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer | EXEMASTANE | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE |
| ER+, HER2- Breast Cancer | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer | KEYNOTE B49 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| Breast Cancer | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer | KEYNOTE B49 | University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| HR+, HER2- | Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes In Advanced Brest Cancer in Asia | MADELINE | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
N/A |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Kuala Lumpur Hospital (HKL) | DR MALWINDER SINGH SANDHU | +603 – 2615 5555, Ext. 1782 / 1783 |
CLICK HERE |
| Sarawak General Hospital | DR VOON PEI JYE | +608 – 2276 820 | CLICK HERE | |||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE | |||
| Hospital Wanita dan Kanak-Kanak Sabah | DR FLORA CHONG LI TZE | +608 – 8522 600, Ext. 2272 | CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | Dr Eznal Izwadi Mohd Mahidin | 603 – 2615 5555, ext 5833 | ||||
| Breast Cancer | A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | SERENA-4 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 010 236 1109 (Wei Ying) |
CLICK HERE | |||
| ER+,HER2-Negative Advanced Breast Cance | Kuala Lumpur Hospital (HKL) | Dr Vaishnavi Jeyasingam | 603 – 2615 5555, ext 5833 | |||
| Breast Cancer | Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) | TENOR | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
N/A |
| Breast Cancer | A Phase III, Randomized, open labelled, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotheraphy in patients with estrogen receptor-positive, HER-2 negative early breast cancer | GO42784 | University of Malaya Medical Centre (UMMC) | |||
| Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | D8532C00001 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603-2296 0888 | CLICK HERE |
| Sarawak General Hospital | DR Syadwa Binti Abdul Shukor | +608 – 2276 820 | CLICK HERE | |||
| Pulau Pinang Hospital | DR CHOONG SWEE HSIA | 603-3362 7700 | CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | DR VAISHNAVI A/P JEYASINGAM | +603 – 2615 5555, Ext. 1620/ 1144 | CLICK HERE | |||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE | |||
| Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | D8532C00002 | Sarawak General Hospital | DR Syadwa Binti Abdul Shukor | +608 – 2276 820 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Colorectal Cancer | A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 Positive Colorectal Cancer | MK4280A-007 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Gastrointestinal Cancers | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers | ASCOLT | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 012 301 0042 (Alice) |
CLICK HERE |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Kuala Lumpur Hospital (HKL) | DR NOOR ZAFIFAH BINTI ZAKARIA | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
CLICK HERE | |||
| Gastrointestinal Cancers | A Phase 3 Double-blinded, two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Perticipants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation | KEYNOTE 937 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
CLICK HERE |
| Gastrointestinal Cancers | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma | KEYNOTE 966 | University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH | 010 – 4346150 (Suganiya) |
CLICK HERE |
| Gastrointestinal Cancers | A phase III, open labelled, Randomised study of Atezolizumab with Lenvatinib or Sorafenib VS Lenvatinib or Sorafenib alone in Hepatocellular Carcinoma previously treated with Atezolizumab and Bevacizumab | MO42541 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Head & Neck Cancer | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). |
KURA | University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| Head and Neck Squamous Cell Carcinoma | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) | KO-TIP-007 | National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK | +603 – 88925555, Ext. 4168 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Advanced Clear Cell Renal Cell Carcinoma | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | MK-6482-012 | Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR | 603-3362 7700 | |
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK | 03- 88925555, ext 4168 | ||||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| Hepatocellular Carcinoma | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | KEYNOTE-937 | National Cancer Institute (IKN) | DR WONG YOKE FUI, Florence | +603 – 8892 5555, Ext. 4168 | CLICK HERE |
| Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE | |||
| Locally advanced or metastatic and/or unresectable HCC | A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab | MO42541 | Beacon Hospital | Dr Tho Lye Mun | +603 – 7786 0845 | CLICK HERE |
| Non-Metastatic Liver Cancer | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete | MK3475-937 | Adventist Penang | Dr. Ang Soo Fan | +604-2227200 | N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Non-small cell lung cancer | A Phase III, Double blind, Randomised, Placebo Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2 IA3 Non small Cell Lung Cancer, following Complete Tumour Resection | ADAURA2 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
N/A |
| Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review |
ARIA | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE | |
| Lung Cancer | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer | ARTOG-OO4 | Pantai Hospital Kuala Lumpur | DR THO LYE MUN | +603 – 2296 0800 | CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE | |||
| Lung Cancer (NSCLC) | A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study). | ATORG001 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) 010 236 1109 (Wei Ying) |
CLICK HERE |
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| Advanced or Metastatic NSCLC | A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation | ATORG003 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | CLICK HERE |
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE | |||
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pulau Pinang Hospital | DR TAN AI LIAN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE | |||
| Non-small Cell Lung Cancer | A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non- squamous Non-Small Cell Lung Cancer [Protocol No. CK-301 301] | CHECKPOINT | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Lung Cancer | Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review | DACOMITINIB | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
CLICK HERE |
| Non-small Cell Lung Cancer | A Two Part Randomized Phase 3 Study of Combination of Cemiplimab (Anti-PDA-1 Antibody) and Platinum Based Doublet Chemotherapy in First Line Treatment of Patients with Advanced o Metastatic Non Small Cell Lung Cancer |
EMPOWER | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Advanced or Metastatic NSCLC | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) | INSIGHT-2 | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR THO LYE MUN | +603 – 2296 0800 | CLICK HERE | |||
| Sunway Medical Centre | Dr Lim Boon Khaw | +603 – 74919191/ 603-8601 1079 | CLICK HERE | |||
| Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer | A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304) | INCMGA 0012-304 | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 -7786 0845 | CLICK HERE |
| Tengku Ampuan Afzan Hospital, Kuantan | DR AISHAH BINTI IBRAHIM | +609 – 5572 922 | CLICK HERE | |||
| Sarawak General Hospital | DR AIDEN HENG FOOK YEW | +608 – 2276 820 | CLICK HERE | |||
| Non-Small Cell Lung Cancer (Stage III) | Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) | LAURA | Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 014 – 9337966 (Kimee Ku) |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | +603 – 7786 0845 | CLICK HERE | |||
| Mount Miriam Cancer Hospital Penang | Dr Ho Kean Fatt | 04-8923906 | ||||
| Advanced or Metastatic NSCLC | A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine | ML41262 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | N/A |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR THO LYE MUN | +603 – 2296 0800 | CLICK HERE | |||
| Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE | |||
| Pulau Pinang Hospital | DR IRFHAN ALI B HYDER ALI | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE | |||
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | Mariposa | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 010 – 4346150 (Suganiya) |
CLICK HERE | |||
| Metastatic Non-Small Cell Lung Cancer | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Papillon | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Advanced NSCLC | Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review | PFIZER A7471067 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | CLICK HERE |
| Recurrent or Metastatic Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer | SAMSON II | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM | +603 – 2615 5555, Ext. 1620 / 1144 |
N/A |
| Non-squamous Non-small Cell Lung Cancer | Raja Perempuan Zainab II Hospital, Kota Bharu | DR AZZA BINTI OMAR | +609 – 7452 636 | |||
| Pulau Pinang Hospital | DR IRFHAN ALI B HYDER ALI | +604 – 2225 767 / 2225 762 / 2225 766 |
||||
| Non-small Cell Lung Cancer | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer | STELLA | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Lung Cancer | A phase 3 study to evaluate zimberelimab (AB122) monotherapy compared to standard chemotherapy of zimberelimab combined with AB154 in front-line, PDL1-Positive, locally advanced or metastatic non-small cell lung cancer | ZIMBERELIMAB (ARC-10) |
University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE | |||
| Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A | |||
| Mount Miriam Cancer Hospital Penang | Dr Ang Tick Suan | 04-8923907 | CLICK HERE | |||
| Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ARC-10 | Tengku Ampuan Afzan Hospital, Kuantan | DR HOW SOON HIN | +609 – 5572 922 | N/A |
| Pulau Pinang Hospital | DR FONG CHIN HENG | +604 – 2225 767 / 2225 762 / 2225 766 |
N/A | |||
| Sarawak General Hospital | DR Lim Yueh Ni | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 / 276 820 |
N/A | |||
| Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | Dr Eznal Izwadi Mohd Mahidin | 603 – 2615 5555, ext 5833 | N/A | |||
| Metastatic Non-Small Cell Lung Cancer | Genomic Profiling Study In Subjects With Locally Advanced/Metastatic Non-Small Cell Lung Cancer | ROCHE | Kuala Lumpur Hospital (HKL) | Dr Ros Suzanna Ahmad Bustamam | 603 – 2615 5555, ext 5833 | N/A |
| A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ARC-10 | Kuala Lumpur Hospital (HKL) | Dr Eznal Izwadi Mohd Mahidin | 603 – 2615 5555, ext 5833 | N/A | |
| Metastatic NSCLC | A Phase II, multicenter, randomized study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel versus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy |
MK7684A-002 | Beacon Hospital Sdn Bhd | Dr Junie Khoo Yu-Yen | +603 – 7786 0845 | CLICK HERE |
| Non-small Cell Lung Cancer | A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy | MK-7684A-002 | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Non-small Cell Lung Cancer | A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer | MK-7684A-003 | Tengku Ampuan Afzan Hospital, Kuantan | DR AISHAH BINTI IBRAHIM | +609-5572923 (ext: 2922/2928) | CLICK HERE |
| Locally advanced or metastatic NSCLC | A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum – pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st / 2nd generation EGFR‑TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) |
CINC280L12301 | Sunway Medical Centre | Dr. Jennifer Leong | +603 – 74919191/ 603-8601 1079 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Ovarian Cancer | A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | EPIK-O | University of Malaya Medical Centre (UMMC) | DR ROZITA ABDUL MALIK | 017 268 0664 (Yok Yong) |
CLICK HERE |
| High-grade serous ovarian cancer | EPIK-O: A phase III, multi-center, randomised (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemo-therapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer | CBYL719K12301 | Hospital Wanita dan Kanak-Kanak Sabah | DR SOON RUEY | 088-522600 ext:2272 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 64091742PCR0002 | Sarawak General Hospital | DR HADI BIN AB.JALIL | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 / 276 820 |
CLICK HERE |
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Metastatic Castration-Sensitive Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration- Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Sarawak General Hospital | DR HADI BIN AB.JALIL | +608 – 227 6666 / 6035 / 276 820 |
CLICK HERE | |||
| National Cancer Institute (IKN) | DR ARNIL GEORGE SIRIMANNE | +603 – 8892 5555, Ext. 4168 | CLICK HERE | |||
| Pulau Pinang Hospital | DR FONG CHIN HENG | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Metastic Prostate Cancer | Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Metastic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | PREVALENCE | Kuala Lumpur Hospital (HKL) | Dr Muthukkumaran Thiagarajan | 603 – 2615 5555, ext 5833 | N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Renal Cancer | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
MK6482-012 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | MK-6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | MK-012 | Kuala Lumpur Hospital (HKL) | Dr Ibtisam Muhamad Nor | Dr Ibtisam Muhamad Nor | N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Sarcoma/Solid Tumor Malignacies | Immune Modulatory Effect of Hyperthermia During Treatment of Recurrent or Metastatic Solid Organ Malignancies | ADIPOLAB-002 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 010 236 1109 (Wei Ying) |
N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Differentiated Thyroid Cancer | A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-Active Iodine Refractory BRAFV600E Mutation-Positive Differentiated Thyroid Cancer | CDRB436J12301 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
The information above was last updated on 7 December 2021.
Source: http://clinicalresearch.my/
Links are from CLINICALTRIAL.GOV
